Today: 11 April 2026
Netflix stock slides as antitrust heat builds on Warner Bros deal
29 January 2026
1 min read

Netflix stock slides as antitrust heat builds on Warner Bros deal

New York, January 29, 2026, 11:29 EST — During regular session

  • Netflix shares slipped roughly 2% in late morning trading
  • Political scrutiny is mounting in both the U.S. and Britain over the proposed Warner Bros tie-up
  • Traders are focused on a Senate antitrust hearing scheduled for next week as the next key catalyst

Shares of Netflix dipped 2.3% to $82.69 in late morning trading Thursday, hitting a session low of $82.37. Investors appeared rattled by growing political scrutiny surrounding the company’s planned Warner Bros Discovery deal.

The stock’s moves have resembled a referendum on the merger. Every fresh cue from regulators or lawmakers tweaks the odds of approval, and the market adjusts quicker than the underlying fundamentals.

It’s significant since Netflix tends to follow the broader growth trend. When the Nasdaq dips amid concerns over big-tech spending, added deal uncertainty only weighs it down further.

Over a dozen UK politicians and ex-policymakers have called on the Competition and Markets Authority to conduct a thorough review of Netflix’s acquisition bid, Reuters reports. Their letter, seen by Reuters, cautioned that the deal would “cement an already dominant player” and pose “a substantial lessening of competition.” Signatories include former culture ministers Chris Smith, Oliver Dowden, Karen Bradley, and ex-BBC director-general Tony Hall. The CMA declined to comment outside of a formal probe, while Netflix and Warner Bros. did not immediately respond to Reuters’ inquiries. Reuters

Wall Street was on edge. The Nasdaq fell roughly 1%, while the S&P 500 dipped 0.33%, weighed down by Microsoft’s decline, which kept pressure on tech stocks after earnings. Investors grappled with another wave of heavy AI spending. “It’s going to be a show me the money story for AI,” said Adam Turnquist, chief technical strategist at LPL Financial. Reuters

Software stocks weighed on the tech sector as J.P. Morgan analysts flagged that “the malaise in software sentiment persists.” Turnquist noted the market seems to be “pricing a worst case scenario” for traditional software amid rising AI competition. Reuters

For Netflix, this context is crucial since the Warner deal discussion unfolds amid a wider market debate over the returns of heavy spending—and just how patient investors will remain.

The downside is clear: if regulators launch deeper investigations or lawmakers use the deal as a test for consolidation, timelines could drag out and headlines grow more critical. In that case, the stock might continue slipping, even without new company developments—particularly if the Nasdaq remains under pressure.

Washington remains the next major checkpoint. On February 3, the Senate Judiciary Committee’s antitrust subcommittee will hold a hearing on the proposed Netflix–Warner deal. Meanwhile, Paramount Skydance, a rival bidder, has pushed back its hostile tender offer deadline to February 20, prolonging the takeover battle.

Stock Market Today

  • Replimune Shares Slump Ahead of FDA Review Amid Negative Technical Signals
    April 11, 2026, 1:01 PM EDT. Replimune Group's stock fell Thursday ahead of an FDA decision due Friday on its RP1 treatment for advanced melanoma, previously rejected in June 2025 due to insufficient evidence from the IGNYTE trial. Internal FDA upheaval reportedly influenced the scrutiny. Shares trade at $5.79, down 20.7% below the 20-day moving average and 30.2% under the 100-day average, signaling weak short-term momentum. The Relative Strength Index (RSI) stands at 35.33, bordering bearish, while the Moving Average Convergence Divergence (MACD) also indicates selling pressure. Despite these challenges, Replimune holds $269.1 million in cash and equivalents, securing runway into early 2027. Over 12 months, the stock declined nearly 20%, reflecting a tough market for the biotech firm.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 1:04 PM EDT Replimune Shares Slump Ahead of FDA Review Amid Negative Technical Signals April 11, 2026, 1:01 PM EDT. Replimune Group's stock fell Thursday ahead of an FDA decision due Friday on its RP1 treatment for advanced melanoma, previously rejected in June 2025 due to insufficient evidence from the IGNYTE trial. Internal FDA upheaval reportedly influenced the scrutiny. Shares trade at $5.79, down 20.7% below the 20-day moving average and 30.2% under the 100-day average, signaling weak short-term momentum. The Relative Strength Index (RSI) stands at 35.33,
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Vale stock price steadies as record 2025 iron ore output meets Brazil permit halt risk
Previous Story

Vale stock price steadies as record 2025 iron ore output meets Brazil permit halt risk

JPMorgan stock price rises above $304 as Fed pause and Washington headlines steer bank shares
Next Story

JPMorgan stock price rises above $304 as Fed pause and Washington headlines steer bank shares

Go toTop